436 related articles for article (PubMed ID: 28639053)
1. Managing the genomic revolution in cancer diagnostics.
Nguyen D; Gocke CD
Virchows Arch; 2017 Aug; 471(2):175-194. PubMed ID: 28639053
[TBL] [Abstract][Full Text] [Related]
2. Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.
Furtado LV; Samowitz WS
Virchows Arch; 2017 Aug; 471(2):235-242. PubMed ID: 28551725
[TBL] [Abstract][Full Text] [Related]
3. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
4. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.
Shimazawa R; Ikeda M
Expert Rev Mol Diagn; 2020 Jun; 20(6):601-610. PubMed ID: 32064968
[TBL] [Abstract][Full Text] [Related]
5. Enabling Precision Oncology Through Precision Diagnostics.
Brown NA; Elenitoba-Johnson KSJ
Annu Rev Pathol; 2020 Jan; 15():97-121. PubMed ID: 31977297
[TBL] [Abstract][Full Text] [Related]
6. Next-generation sequencing and its applications in molecular diagnostics.
Su Z; Ning B; Fang H; Hong H; Perkins R; Tong W; Shi L
Expert Rev Mol Diagn; 2011 Apr; 11(3):333-43. PubMed ID: 21463242
[TBL] [Abstract][Full Text] [Related]
7. Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?
Tripathy D; Harnden K; Blackwell K; Robson M
BMC Med; 2014 Aug; 12():140. PubMed ID: 25286031
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine for cancer with next-generation functional diagnostics.
Friedman AA; Letai A; Fisher DE; Flaherty KT
Nat Rev Cancer; 2015 Dec; 15(12):747-56. PubMed ID: 26536825
[TBL] [Abstract][Full Text] [Related]
9. Potential of whole-genome sequencing-based pharmacogenetic profiling.
Caspar SM; Schneider T; Stoll P; Meienberg J; Matyas G
Pharmacogenomics; 2021 Feb; 22(3):177-190. PubMed ID: 33517770
[TBL] [Abstract][Full Text] [Related]
10. Molecular profiling of sarcomas: new vistas for precision medicine.
Al-Zaid T; Wang WL; Somaiah N; Lazar AJ
Virchows Arch; 2017 Aug; 471(2):243-255. PubMed ID: 28664413
[TBL] [Abstract][Full Text] [Related]
11. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
12. Cancer diagnostics: The journey from histomorphology to molecular profiling.
Ahmed AA; Abedalthagafi M
Oncotarget; 2016 Sep; 7(36):58696-58708. PubMed ID: 27509178
[TBL] [Abstract][Full Text] [Related]
13. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life.
Morganti S; Tarantino P; Ferraro E; D'Amico P; Viale G; Trapani D; Duso BA; Curigliano G
Crit Rev Oncol Hematol; 2019 Jan; 133():171-182. PubMed ID: 30661654
[TBL] [Abstract][Full Text] [Related]
14. Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine.
Kotelnikova EA; Pyatnitskiy M; Paleeva A; Kremenetskaya O; Vinogradov D
Oncotarget; 2016 Aug; 7(32):52493-52516. PubMed ID: 27191992
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.
Wakai T; Prasoon P; Hirose Y; Shimada Y; Ichikawa H; Nagahashi M
Int J Clin Oncol; 2019 Feb; 24(2):115-122. PubMed ID: 30515675
[TBL] [Abstract][Full Text] [Related]
16. [Cancer: three eras of personalized medicine].
Jordan B
Med Sci (Paris); 2017 Oct; 33(10):905-908. PubMed ID: 28994388
[TBL] [Abstract][Full Text] [Related]
17. Clinical and Technical Aspects of Genomic Diagnostics for Precision Oncology.
Sheikine Y; Kuo FC; Lindeman NI
J Clin Oncol; 2017 Mar; 35(9):929-933. PubMed ID: 28297627
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways.
Doherty M; Metcalfe T; Guardino E; Peters E; Ramage L
Ann Oncol; 2016 Aug; 27(8):1644-6. PubMed ID: 27117532
[No Abstract] [Full Text] [Related]
19. Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations.
Allegretti M; Fabi A; Buglioni S; Martayan A; Conti L; Pescarmona E; Ciliberto G; Giacomini P
J Exp Clin Cancer Res; 2018 Mar; 37(1):47. PubMed ID: 29506529
[TBL] [Abstract][Full Text] [Related]
20. CDx, NGS and regulation: five perspectives from the Pistoia Alliance.
Wise J; Furness M; McWilliams S; Patton S
Drug Discov Today; 2019 Nov; 24(11):2120-2125. PubMed ID: 31306783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
